Merrimack Pharma (MACK) Tops Q3 EPS by 4c; Lowers, Narrows FY16 Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
BTIG Remains Neutral on Merrimack Pharma (MACK) Following Q3 Report, Restructuring
November 10, 2016 11:44 AM ESTBTIG affirms Merrimack Pharma (Nasdaq: MACK) at Neutral following Q3 results and announced restructuring.
Analyst Ling Wang commented, Q16 ONIVYDE net revenues of $14.5M slightly missed consensus ($16.6M) and our estimate ($16.7M). It ended 3Q16 with cash & equivalents of $48.5M. Management provided updated... More
